Last reviewed · How we verify

baricitinib treatment — Competitive Intelligence Brief

baricitinib treatment (baricitinib treatment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: JAK inhibitor. Area: Immunology.

phase 3 JAK inhibitor JAK Immunology Small molecule Live · refreshed every 30 min

Target snapshot

baricitinib treatment (baricitinib treatment) — University Hospital, Bordeaux. Baricitinib is a Janus kinase (JAK) inhibitor that blocks the activity of JAK enzymes, which play a role in inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
baricitinib treatment TARGET baricitinib treatment University Hospital, Bordeaux phase 3 JAK inhibitor JAK
Pf-07293893 pf-07293893 Pfizer marketed JAK inhibitor Janus kinase (JAK) pathway Not available
Leqselvi DEURUXOLITINIB Sun Pharm Inds Inc marketed JAK1, JAK2, TYK2 2024-01-01
Litfulo Ritlecitinib Tosylate Pfizer marketed Kinase inhibitor Janus kinase 3 (JAK3) and tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family 2023-01-01
Cibinqo Abrocitinib Pfizer marketed Janus Kinase Inhibitor [EPC] Tyrosine-protein kinase JAK1 2022-01-01
Cibinqo abrocitinib Pfizer marketed Janus Kinase Inhibitor [EPC] Tyrosine-protein kinase JAK1 2022-01-01
Vonjo PACRITINIB Sobi marketed Kinase Inhibitor [EPC] Tyrosine-protein kinase JAK2 2022-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (JAK inhibitor class)

  1. Pfizer · 19 drugs in this class
  2. Aclaris Therapeutics, Inc. · 2 drugs in this class
  3. Beijing Friendship Hospital · 2 drugs in this class
  4. Azienda Ospedaliero, Universitaria Pisana · 1 drug in this class
  5. CAGE Bio Inc. · 1 drug in this class
  6. CTI BioPharma · 1 drug in this class
  7. Celgene · 1 drug in this class
  8. Fred Hutchinson Cancer Center · 1 drug in this class
  9. LEO Pharma · 1 drug in this class
  10. McMaster University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). baricitinib treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/baricitinib-treatment. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: